A new treatment showing promise for generalized anxiety disorder (GAD) involves an LSD-based drug called MM120 (lysergide d-tartrate). This treatment has received breakthrough designation from the FDA.
MM120: A Potential Breakthrough for GAD
MindMed Inc is developing MM120, and its breakthrough designation by the FDA is based on positive data from a phase 2b clinical trial. This suggests the FDA recognizes its potential to offer a significant improvement over existing therapies for GAD.
Key Aspects of MM120
- Active Ingredient: Lysergide d-tartrate (LSD-based)
- Developer: Mind Medicine (MindMed) Inc
- Status: Received breakthrough designation from the FDA
- Target Condition: Generalized Anxiety Disorder (GAD)
- Data Basis: Promising topline data from a phase 2b clinical trial
